Skip to contentpdufa.bio

Klygefa (gefurulimab-gaks)

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

The FDA approved Klygefa (gefurulimab-gaks) on Nov 13, 2026. 1 FDA decision on record below.

AZN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Nov 13, 2026 (announced Nov 16, 2026) ✓ ApprovedAZN

Specialist biotech funds holding AZN, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors379,300$61.8 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Klygefa (gefurulimab-gaks)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for Klygefa (gefurulimab-gaks); 1 FDA decision is on record below.

What happened at Klygefa (gefurulimab-gaks)'s most recent FDA decision?

On Nov 13, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has Klygefa (gefurulimab-gaks) been approved by the FDA?

Yes. The FDA approved an application for Klygefa (gefurulimab-gaks) on Nov 13, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.